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Background: Although in use as an antidiabetic agent, pioglitazone, peroxisome proliferator activated receptor-r agonist, is also an intriguing 
inflammatory-modulating agent that may reduce cardiovascular death, myocardial infarction, and stroke. However, few data exist on whether 
pioglitazone on top of statin further attenuates plaque inflammation in humans. To address this open question, we harnessed serial 18F-FDG PET/CT 
to assess longitudinal spatial alterations in plaque inflammation induced by pioglitazone on top of statin.
methods: This is a prospective, open-labeled, randomized controlled study in statin-naïve patients with coronary, carotid, aortic atherosclerotic 
plaques. After undergoing FDG PET/CT of both carotid and thoracic aorta, patients were randomly assigned to atorvastatin 20 mg/day or atorvastatin 
20 mg/day plus pioglitazone 30 mg/day for 3 months, followed by a second FDG PET/CT of the same arteries. Primary endpoint was changes in 
arterial inflammation defined as Δ average target-to-background ratio (ΔTBR) of arterial signal intensity to adjacent vein signal intensity between 
initial and a second FDG PET/CT.
results: Of 1,100 screened patients, 35 patients were finally randomized to atorvastatin only (17 patients) or atorvastatin plus pioglitazone 
treatment (18 patients). 27 patients were non-diabetic patients and 8 patients were on glycemic control. Two groups showed similar serum hsCRP, 
LDL, and HbA1C levels. As expected, both groups achieved a significant reduction in average TBRs of 3 arteries after 3-month treatment. However, 
pioglitaozone failed to further confer additional reduction in ΔTBR (pioglitazone 5.08±2.02% vs. atorvastatin 4.55±3.61%, p>0.1).
conclusions: Serial FDG PET/CT of arteries demonstrates that pioglitazone does not confer additional antiatheorsclerotic effect in patients who 
receive adequate dose of statin.
